发布求助
文献互助 智能选刊 最新文献

Formulary最新文献

筛选
英文 中文
An ADR surveillance program: increasing quality, number of incidence reports. 不良反应监测规划:提高发生率报告的质量和数量。
Formulary Pub Date : 1995-08-01
M J Orsini, P A Orsini, D B Thorn, J N Gallina
{"title":"An ADR surveillance program: increasing quality, number of incidence reports.","authors":"M J Orsini,&nbsp;P A Orsini,&nbsp;D B Thorn,&nbsp;J N Gallina","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An Adverse Drug Reaction Surveillance Program (ADRSP) was implemented by the pharmacy department of the University of Maryland Medical System to address the institution's underreporting of adverse drug reactions. The program aims were to increase the number and quality of significant adverse drug reaction (ADR) reports by facilitating and standardizing the reporting process, to more actively involve the pharmacy staff, and to create a comprehensive database, thus enabling the intervention of future untoward events. During the program's first 2 years, the number of ADR reports more than doubled, primarily due to increased pharmacists' participation. The ADRSP has facilitated the reporting process, enhanced the submission of ADR reports to the FDA, and helped prevent ADRs.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 8","pages":"454-61"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased adverse drug reaction reporting through wall-mounted ADR reporting cards. 通过壁挂式ADR报告卡增加药物不良反应报告。
Formulary Pub Date : 1995-08-01
B A Szymusiak-Mutnick, M B Ross
{"title":"Increased adverse drug reaction reporting through wall-mounted ADR reporting cards.","authors":"B A Szymusiak-Mutnick,&nbsp;M B Ross","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To increase adverse drug reaction reporting, the Pharmacy Department Quality Assessment and Improvement Committee at the University of Iowa Hospitals and Clinics created an abbreviated wall-mounted adverse drug reaction card on \"tear-off\" pads. This report discusses strategies the Committee identified in order to attain its goal.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 8","pages":"471-3"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Will politics sidetrack FDA reform? 政治会影响FDA的改革吗?
Formulary Pub Date : 1995-08-01
B Gatty
{"title":"Will politics sidetrack FDA reform?","authors":"B Gatty","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 8","pages":"476, 475"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results of our national survey. Current formulary decision-making strategies and new factors influencing the process. 这是我们全国调查的结果。现行的公式决策策略和影响过程的新因素。
Formulary Pub Date : 1995-08-01
{"title":"Results of our national survey. Current formulary decision-making strategies and new factors influencing the process.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Formulary recently conducted a survey of 2,000 of its readers to uncover what forces are at play in their formulary decision-making processes. Topics included general philosophies toward formulary decision making, philosophies toward adding and deleting products, influences on the process, trends related to product reviews, formulary management strategies, drug information educational strategies, and new approaches to the formulary decision-making process. Some 295 surveys (14.75%) were returned. Highlights and analyses of the survey findings are presented for your review and comparison with your practice setting's approaches.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 8","pages":"462-70"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA says 'Look at the facts' when judging its record on drug approvals. 美国食品药品监督管理局(FDA)说，在评判其药物批准记录时，要“看事实”。
Formulary Pub Date : 1995-07-01
B Gatty
{"title":"FDA says 'Look at the facts' when judging its record on drug approvals.","authors":"B Gatty","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 7","pages":"412, 411"},"PeriodicalIF":0.0,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy. 使用决策分析评估非格昔汀(G-CSF)治疗的成本和收益。
Formulary Pub Date : 1995-07-01
J A Peroutka, A H Mutnick
{"title":"Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.","authors":"J A Peroutka,&nbsp;A H Mutnick","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The FDA's approval of filgrastim (granulocyte colony-stimulating factor [G-CSF]) for accelerated recovery of neutrophil counts following chemotherapy has prompted discussions regarding the cost and benefits associated with such expensive new therapies. One method to evaluate the cost effectiveness of a therapy is decision analysis, which provides a quantitative method of cost analysis. Using the principles of decision analysis, we created a decision-analysis tree for evaluating the cost effectiveness of G-CSF therapy. Based on data gathered from a retrospective review of ambulatory oncology patients, we found that routine administration of G-CSF to all outpatients receiving chemotherapy is not cost effective, although it would be justifiable for some patients.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 7","pages":"394-5, 400-4"},"PeriodicalIF":0.0,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Pegaspargase与天冬酰胺酶在成人ALL中的作用:药物经济学评估。
Formulary Pub Date : 1995-07-01
B G Peters, B J Goeckner, J J Ponzillo, W S Velasquez, A L Wilson
{"title":"Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.","authors":"B G Peters,&nbsp;B J Goeckner,&nbsp;J J Ponzillo,&nbsp;W S Velasquez,&nbsp;A L Wilson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Asparaginase is an effective treatment for patients with acute lymphocytic leukemia (ALL). Unfortunately, asparaginase therapy is associated with a high incidence of hypersensitivity reactions (up to 73%), including life-threatening anaphylaxis, and its half-life of approximately 20 hours necessitates daily administration. Pegaspargase, a modification of L-asparaginase, has a longer half-life (357 hours), a decreased incidence of hypersensitivity reactions, and when doses every 14 days, provides comparable efficacy to asparaginase; however, it is much more expensive per single-dose vial ($980.00 vs $52.38). To determine the pharmacoeconomic impact of the two agents, we conducted a cost-minimization analysis for three common adult ALL protocols. Results showed that pegaspargase was significantly less costly to payers on an inpatient or outpatient basis and warranted addition to our formulary.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 7","pages":"388-93"},"PeriodicalIF":0.0,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21023194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dosing guidelines for foscarnet and trimetrexate. 氟膦酸酯和三甲氨蝶呤的剂量指南。
Formulary Pub Date : 1995-06-01
J M Wooten, K Chase, M C O'Connor, R B Henry
{"title":"Dosing guidelines for foscarnet and trimetrexate.","authors":"J M Wooten,&nbsp;K Chase,&nbsp;M C O'Connor,&nbsp;R B Henry","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The P & T Committee at Trinity Lutheran Hospital, a 320-bed, community/teaching hospital in Kansas City, MO, has developed dosing and monitoring guidelines for foscarnet sodium (Foscavir) and trimetrexate glucuronate (Neutrexin)--two drugs used to treat patients with opportunistic infections associated with the human immunodeficiency virus (HIV). Presented in this Experience Brief is a short discussion of these drugs, the rationale for guideline development, and the actual dosing and monitoring protocols devised.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 6","pages":"349-52"},"PeriodicalIF":0.0,"publicationDate":"1995-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21016494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Criteria-based antimicrobial i.v. to oral conversion program. 以标准为基础的抗菌素静脉注射到口服转化方案。
Formulary Pub Date : 1995-06-01
A U Okpara, J J Maswoswe, K Stewart
{"title":"Criteria-based antimicrobial i.v. to oral conversion program.","authors":"A U Okpara,&nbsp;J J Maswoswe,&nbsp;K Stewart","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Collaborative efforts among several departments and the P & T Committee resulted in an IV to oral conversion program for select antimicrobials in our 580-bed county teaching hospital. This criteria-based program was designed to monitor and educate physicians on the appropriateness of parenteral antimicrobial prescribing, ensure rapid transition from IV to oral therapy, and contain costs. In the first 2 months of the program, 78 patients were converted from IV to oral administration with an estimated savings of $12,935. Of the ordering physicians, 66 (84.6%) accepted the interventions. All patients who switched administration routes were successfully treated with an oral agent. This program also has had a positive effect on patient outcomes and physician prescribing habits.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 6","pages":"343-8"},"PeriodicalIF":0.0,"publicationDate":"1995-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21016493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing a disease management program: how to get started. 设计疾病管理程序:如何开始。
Formulary Pub Date : 1995-06-01
E R Gonzalez, V S Crane
{"title":"Designing a disease management program: how to get started.","authors":"E R Gonzalez,&nbsp;V S Crane","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To successfully design and implement disease management programs, clinicians must understand the disease's natural course and cost drivers, base the diagnosis and treatment on the disease process and not the reimbursement schedules, educate and reinforce compliance to improve treatment outcomes, and focus on commonly occurring and costly chronic diseases. This article describes a 7-step process for developing a disease management program based on those concepts. The changing role and functions of the P & T Committee in disease management programs are also presented.</p>","PeriodicalId":12354,"journal":{"name":"Formulary","volume":"30 6","pages":"326-8, 331-3, 337-40"},"PeriodicalIF":0.0,"publicationDate":"1995-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21016492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信